J.P. Morgan Sticks to Their Buy Rating for Ascendis Pharma (ASND)
J.P. Morgan analyst Jessica Fye maintained a Buy rating on Ascendis Pharma (ASND – Research Report) today and set a price target of $167.00.
J.P. Morgan Remains a Buy on Intra-Cellular Therapies (ITCI)
In a report released on January 27, Jessica Fye from J.P. Morgan maintained a Buy rating on Intra-Cellular Therapies (ITCI – Research Report), ...
Le Lézard2h
ISPE Announces 2025 Facility of the Year Awards (FOYA) Submission Finalists as FOYA Celebrates its 20-Year Anniversary
The International Society of Pharmaceutical Engineering (ISPE) has announced the 2025 Facility of the Year submission finalists. Each of the submission finalists' projects succeeded in meeting the ...
BRAF Inhibitors Market to Register Incremental Growth During the Study Period (2020–2034) | DelveInsight
The BRAF Inhibitors market is expected to grow significantly in the coming years. This is due to the increasing number of patients being diagnosed with cancer, rise in biomarker testing rates, the ...